Durect Corp (DRRX) Stock Price, Quote & News

Company Profile

DURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product candidate includes larsucosterol, an endogenous, orally bioavailable small molecule to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as for the treatment of patients with metabolic dysfunction-associated steatohepatitis. The company also offers POSIMIR,...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 408 777 1417

Fax: 408 777 3577

Website: www.durect.com

Address:

10240 Bubb Road, Cupertino, United States

Glene Jul. 7 at 2:03 PM

$DRRX Any word on how the test is going?

0 · Reply

Gernbcrx May. 17 at 2:03 AM

$DRRX Bigbulldaddy. Actually we get CVR payments on total annual net sales for ANY indication so I hope you are right about exploring other options outside of AH.

0 · Reply

Glene May. 14 at 12:30 AM

$BHC $DRRX how much are you figuring per share?

1 · Reply

bigbulldaddy May. 13 at 11:02 PM

$BHC $DRRX Currently as of May Larsucosterol trial has 5/48 sites recruiting for 350 patient phase 3. Heads up to my people we are starting to move. Hope it’s quick. Good luck my LONG token holders… I did the math for myself: Assuming google is right I’m expecting… $288,000 at 500 million in sales $384,000 at 1 billion in sales Bausch is also looking at other R&D targets for Larsucosterol per info which we don’t get any money on… lol they literally called it REAHFIRM

1 · Reply

ABELTR Apr. 7 at 2:38 PM

$DRRX Hell

1 · Reply

ABELTR Feb. 17 at 1:20 PM

$DRRX so, where are we with this guy ?

0 · Reply

msufans Jan. 28 at 5:07 PM

$DRRX i accepted the tender offer. The cash i received from the tender offer does not show up on my 1099. I have Schwab account. Does it happen to anyone? How will we treat the transaction for tax purposes then?

1 · Reply

Merlintrader Nov. 22 at 6:52 AM

$DRRX https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

Invest2live Oct. 11 at 3:13 PM

$DRRX 246% already; congrats 🎊 🎉🎈 Checkout $CUE and $LCTX

0 · Reply

bigbulldaddy Oct. 1 at 7:51 PM

$DRRX In the end I lost $100,000 here. But could still do ok if it works out… 38,000 shares for milestones… Thank goodness for the PLTR call I made… just cancelled this out and allowed me to redistribute into dividend assets. Payday may come later. No expectations… 500 million revenue surely takes 5 years from now assuming it’s approved.

1 · Reply

Bausch Health Announces Extension of DURECT Corporation Tender Offer to September 10, 2025

BHC

Aug 12, 2025, 4:30 PM EDT - 1 year ago

DURECT Corporation Reports Second Quarter 2025 Financial Results and Provides Update on Proposed Acquisition by Bausch Health

Jul 29, 2025, 7:00 AM EDT - 1 year ago

Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease

BHC

May 13, 2025, 4:05 PM EDT - 1 year ago

DURECT Corporation Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 26, 2025, 4:05 PM EDT - 1 year ago

DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:30 PM EDT - 1 year ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update

Feb 4, 2025, 7:30 AM EST - 1 year ago

DURECT Corporation to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 10:09 AM EST - 1 year ago

DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

Nov 25, 2024, 6:00 AM EST - 1 year ago

DURECT Corporation Announces Sale of ALZET® Product Line to Lafayette Instrument Co. for $17.5 Million

Nov 13, 2024, 4:01 PM EST - 1 year ago

DURECT Corporation Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 6, 2024, 4:45 PM EST - 1 year ago

DURECT Corporation to Announce Third Quarter 2024 Financial Results and Provide a Business Update

Oct 17, 2024, 8:30 AM EDT - 1 year ago

DURECT Corporation to Present Data on Larsucosterol at The Liver Meeting 2024

Sep 25, 2024, 8:00 AM EDT - 1 year ago

DURECT Corporation Announces Phase 3 Registrational Trial Design for Larsucosterol in Alcohol-associated Hepatitis

Sep 4, 2024, 4:30 PM EDT - 2 years ago

DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference

Aug 13, 2024, 4:01 PM EDT - 2 years ago

DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update

Aug 7, 2024, 4:30 PM EDT - 2 years ago

DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update

May 21, 2024, 8:00 AM EDT - 2 years ago

DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis

May 13, 2024, 4:05 PM EDT - 2 years ago

DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update

May 7, 2024, 4:30 PM EDT - 2 years ago

DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update

Apr 30, 2024, 7:00 AM EDT - 2 years ago

DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis

Mar 27, 2024, 4:01 PM EDT - 2 years ago

DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 20, 2024, 4:30 PM EDT - 2 years ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update

Mar 4, 2024, 7:00 AM EST - 2 years ago

DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

Feb 7, 2024, 6:48 PM EST - 2 years ago

DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Nov 13, 2023, 4:05 PM EST - 2 years ago

DURECT Corporation Reports Third Quarter 2023 Financial Results and Business Update

Nov 9, 2023, 4:30 PM EST - 2 years ago

DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update

Nov 7, 2023, 4:01 PM EST - 2 years ago

DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality

Sep 7, 2023, 7:00 AM EDT - 3 years ago

DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

Aug 31, 2023, 4:30 PM EDT - 3 years ago

DURECT Corporation Announces Presentations in Upcoming Investor Conferences

Aug 9, 2023, 4:05 PM EDT - 3 years ago

DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update

Aug 3, 2023, 4:30 PM EDT - 3 years ago

DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update

Jul 20, 2023, 8:00 AM EDT - 3 years ago

DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jun 7, 2023, 6:00 AM EDT - 3 years ago

DURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis

May 8, 2023, 4:05 PM EDT - 3 years ago

DURECT Corporation Reports First Quarter 2023 Financial Results and Business Update

May 1, 2023, 7:03 PM EDT - 3 years ago

DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8

Apr 27, 2023, 5:11 PM EDT - 3 years ago

DURECT Corporation to Host KOL Event on Alcohol-Associated Hepatitis

Apr 25, 2023, 6:45 PM EDT - 3 years ago

DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference

Apr 10, 2023, 6:00 AM EDT - 3 years ago

DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated Hepatitis

Mar 21, 2023, 4:30 PM EDT - 3 years ago

DURECT Corporation Announces Appointment of Gail Maderis as Chair of the Board

Mar 9, 2023, 8:30 AM EST - 3 years ago

DURECT Corporation Fireside Chat at the Oppenheimer 33rd Annual Healthcare Conference

Mar 7, 2023, 4:05 PM EST - 3 years ago

DURECT Corporation Reports Fourth Quarter and Full Year 2022 Financial Results and AHFIRM Trial Update

Feb 28, 2023, 6:07 PM EST - 3 years ago

DURECT Corporation to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 7

Feb 3, 2023, 5:17 PM EST - 3 years ago

DURECT Corporation Announces $10 Million Registered Direct Offering of Common Stock and Warrants

Nov 28, 2022, 6:46 PM EST - 3 years ago

DURECT Announces 1-for-10 Reverse Stock Split

Nov 2, 2022, 4:05 PM EDT - 4 years ago

DURECT Corporation Reports Third Quarter 2022 Financial Results and Update of Programs

Oct 26, 2022, 8:30 AM EDT - 4 years ago

DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2

Oct 6, 2022, 8:30 AM EDT - 4 years ago

DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial

Sep 26, 2022, 8:30 AM EDT - 4 years ago

Innocoll and DURECT Announce U.S. launch of POSIMIR®

Glene Jul. 7 at 2:03 PM

$DRRX Any word on how the test is going?

0 · Reply

Gernbcrx May. 17 at 2:03 AM

$DRRX Bigbulldaddy. Actually we get CVR payments on total annual net sales for ANY indication so I hope you are right about exploring other options outside of AH.

0 · Reply

Glene May. 14 at 12:30 AM

$BHC $DRRX how much are you figuring per share?

1 · Reply

bigbulldaddy May. 13 at 11:02 PM

1 · Reply

ABELTR Apr. 7 at 2:38 PM

$DRRX Hell

1 · Reply

ABELTR Feb. 17 at 1:20 PM

$DRRX so, where are we with this guy ?

0 · Reply

msufans Jan. 28 at 5:07 PM

1 · Reply

Merlintrader Nov. 22 at 6:52 AM

$DRRX https://www.youtube.com/shorts/_DSnrdOwvBg

0 · Reply

Invest2live Oct. 11 at 3:13 PM

$DRRX 246% already; congrats 🎊 🎉🎈 Checkout $CUE and $LCTX

0 · Reply

bigbulldaddy Oct. 1 at 7:51 PM

1 · Reply

ChristopherClothier501 Sep. 21 at 9:03 AM

$DRRX Biotech with phase II data. High risk speculation. Trading near cash value. No pattern.

0 · Reply

RRNC Sep. 13 at 2:44 PM

$DRRX My cost basis is much higher than 1.75$ .Will the loss be counted as capital loss for next year tax filing?

2 · Reply

msufans Sep. 12 at 11:16 PM

$DRRX when will we receive the cash? I am with Schwab.

1 · Reply

brunoq14 Sep. 12 at 12:31 PM

$DRRX Goodbye Durect. A merger takes care of the rest of the shares.

0 · Reply

LeftyT Sep. 11 at 1:57 PM

$DRRX Well folks, 62% of shareholders tendered their shares so it's a done deal now. We all get $1.75 for each of our shares and a CVR from Bausch for each share we own. I wish Bausch Health (BHC) the best success in rapidly advancing Larsucosteral through a P3 and FDA approval. This drug has great potential IMHO and many, many lives could be saved with its approval. All the best to Mr Brown. He made a valiant effort to get this across the finish line. Now he can enjoy his retirement and watch a real pharma company take this to market. He will have a ton of CVR's from his shares, so you know he'll do whatever he can to help them advance this drug quickly.

0 · Reply

TwongStocks Sep. 11 at 12:41 PM

$BHC Completes Acquisition of $DRRX, Expanding Late-stage Liver Disease Portfolio https://www.prnewswire.com/news-releases/bausch-health-completes-acquisition-of-durect-corporation-expanding-late-stage-liver-disease-portfolio-302553904.html DRRX shares were halted last night by NASDAQ. Shareholders will receive $1.75 and a CVR per share. If you owned 1000 DRRX, you will get $1750 and 1000 CVRs in your account. May take a few days for brokers to process the transaction into your accounts.

0 · Reply

bnjhnsn Sep. 11 at 12:10 PM

$DRRX well folks, it looks like the deal is done. Take your shiny pennies and dont lose track of those CVR's. Best of luck all!

0 · Reply

FreeBeerTomorrow Sep. 11 at 7:50 AM

$DRRX DRRX Tender Offer: Bausch Health is in the process of acquiring DRRX through a tender offer. They have offered to buy all outstanding shares of DRRX for $1.75 per share in cash, plus a contingent value right (CVR) that could provide additional payments based on future sales milestones. Tender Offer Expiration: The most recent public announcement indicates that the tender offer was extended to expire at 5:00 p.m. New York City time on September 10, 2025. Merger After Tender Offer: The definitive merger agreement states that as soon as practicable after the tender offer is successfully completed (meaning Bausch Health acquires a majority of the outstanding shares), Bausch Health will merge its subsidiary with and into DURECT. Any remaining shares of DRRX will be converted into the right to receive the same per-share consideration ($1.75 cash plus the CVR).

0 · Reply

mpcfishn Sep. 11 at 1:37 AM

$DRRX im not understanding what's going on, will I lose my shares? How does this work? I'm using RH.

1 · Reply

LeftyT Sep. 10 at 5:36 PM

$DRRX So how does this work???? According to yesterday's Form 4 the CFO gets 110,000 sh stock option grant w/ a strike of 1.30/sh just 2 days before the tender off deadline. "The option will vest and become exercisable in installments of one- sixteenth of the total number of shares at the end of each 3 month period following the grant date". Are these options essentially worthless, or is there a clause that allows for complete vesting upon significant (already agreed to) ownership change? Inquiring minds want to know!!! http://archive.fast-edgar.com/20250909/AA2Z5G23ZC22LZ78222N2Z429P5UZK22ZN72

2 · Reply

Nabors5 Sep. 9 at 2:39 AM

$DRRX If I do nothing with my current shares does that mean I am accepting the tinder offer? Do the current Drrx shares I own transfer to BHC shares?

1 · Reply

Nabors5 Sep. 9 at 2:36 AM

$DRRX

0 · Reply

Market Cap	59.31M
Revenue (ttm)	2.03M
Net Income (ttm)	-8.32M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-409.85%
Debt to Equity Ratio	0.00

Volume	2,787,600
Avg Vol	1,467,000
Day's Range	N/A - N/A
Shares Out	31.05M
Stochastic %K	14%
Beta	0.92
Analysts	Hold
Price Target	$2.50